Pharmaceutical

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

Next Article

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about Lilly plant problems, FDA reorganization plans, and more

STAT+: Pharmalittle: We’re reading about Lilly plant pr...

Jan 22, 2024

Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda

Pfizer and Astellas seek updated EMA approval for Padce...

Jan 29, 2024

Eli Lilly’s partnership with Amazon to boost presence in diabetes and obesity markets

Eli Lilly’s partnership with Amazon to boost presence i...

Mar 20, 2024